Pharmaceutical

WCG Reduces Clinical Trial Protocol Deviations by 35-50% with the Launch of Total Training, the First Comprehensive Solution for Improved Site Readiness, Engagement, and Compliance

CARY, N.C., Aug. 25, 2025 /PRNewswire/ -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical...

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026...

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their...

error: Content is protected !!